Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy

被引:22
|
作者
Weinberg, Adriana [1 ]
Dickover, Ruth [2 ]
Britto, Paula [3 ]
Hu, Chengcheng [3 ]
Patterson-Bartlett, Julie [1 ]
Kraimer, Joyce [4 ]
Gutzman, Howard [5 ]
Shearer, William T. [6 ]
Rathore, Mobeen [7 ]
McKinney, Ross [8 ]
机构
[1] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[3] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA
[4] Social & Sci Syst Inc, Silver Spring, MD USA
[5] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA
[6] Texas Childrens Hosp, Houston, TX 77030 USA
[7] Univ Florida, Coll Med, Jacksonville, FL USA
[8] Duke Univ, Med Ctr, Durham, NC USA
基金
美国国家卫生研究院;
关键词
candida; cell-mediated immunity; children; highly active antiretroviral therapy; HIV; T-cell rearrangement excision circle; T-cell subpopulations;
D O I
10.1097/QAD.0b013e3283189bb3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The goal of HAART is to promote reconstitution of CD4(+) T cells and other immune responses. We evaluated the extent and the kinetics of immune reconstitution in HIV-infected children over 144 weeks of successful HAART. Methods: Thirty-seven children receiving their first HAART regimen had plasma HIV RNA; T cells and subpopulations; T-cell rearrangement excision circles (TREC) DNA; candida, HIV(CD4) and HIV(CD8) enzyme-linked immunospot measured at regular intervals. Results: Plasma HIV RNA became undetectable in 81% of patients at 24 weeks and remained undetectable in 77% at 144 weeks. In contrast, CD4(+)% continuously increased. Distribution of T-cell subpopulations changed rapidly during the first 48 weeks of HAART and more slowly thereafter. At 144 weeks, total, naive and activated CD4(+)% and naive CD8(+)% of HIV-infected children were not significantly different from those of healthy age-matched controls, whereas total and activated CD8(+)% remained elevated. CD4(+) and CD8(+) TREC content increased only during the first 48 weeks of HAART. They positively correlated with each other and with total CD4(+)%, naive CD4(+)% and naive CD8(+)%. Candida and HIV(CD4) enzyme-linked immunospot increased over time reaching peak values at 48 weeks and 144 weeks, respectively. HIVCD8 enzyme-linked immunospot decreased in magnitude over 144 weeks of HAART but retained its breadth. Baseline CD4(+)% positively correlated with CD4(+)% and with functional immune reconstitution at week 144, whereas baseline TREC correlated with TREC at week 144. Conclusion: HIV-infected children acquired normal distribution of CD4(+) T cells and other subpopulations and recovered CD4-mediated HIV immunity after 144 weeks of HAART. (C) 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:2267 / 2277
页数:11
相关论文
共 50 条
  • [1] Antiretroviral therapy in HIV-infected children
    Fan, Conghai
    Zhang, Fengchao
    Chen, Chao
    MINERVA PEDIATRICA, 2019, 71 (05) : 455 - 460
  • [2] Immune reconstitution inflammatory syndrome after initiating highly active antiretroviral therapy in HIV-infected children
    Kilborn, Tracy
    Zampoli, Marco
    PEDIATRIC RADIOLOGY, 2009, 39 (06) : 569 - 574
  • [3] Immune reconstitution inflammatory syndrome after initiating highly active antiretroviral therapy in HIV-infected children
    Tracy Kilborn
    Marco Zampoli
    Pediatric Radiology, 2009, 39
  • [4] Antiretroviral Therapy in HIV-Infected Infants and Children
    Maron, Gabriela
    Gaur, Aditya H.
    Flynn, Patricia M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (04) : 360 - 363
  • [5] Measles Seropositivity in HIV-infected Kenyan Children on Antiretroviral Therapy
    Newman, Laura P.
    Njoroge, Anne
    Ben-Youssef, Leila
    Merkel, Michele
    Gatuguta, Ann
    Ton, Quy
    Obimbo, Elizabeth Maleche
    Wamalwa, Dalton
    Lohman-Payne, Barbara
    Richardson, Barbra A.
    Nduati, Ruth
    Farquhar, Carey
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 843 - 845
  • [6] Antiretroviral drugs in HIV-infected children
    Vigano, Alessandra
    Manfredini, Valeria
    Penagini, Francesca
    Giacomet, Vania
    Zuccotti, Gian Vincenzo
    PHARMACOLOGICAL RESEARCH, 2011, 64 (01) : 1 - 3
  • [7] When to initiate antiretroviral therapy in HIV-infected children?
    Thuret, I
    ARCHIVES DE PEDIATRIE, 2004, 11 (12): : 1521 - 1524
  • [8] Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
    Mantes Gil, Am Cecilia
    Lorenzetti, Raquel
    Mendes, Gun Bergsten
    Morcillo, Andre Moreno
    Dalbo Contreras Toro, Adyleia Aparecida
    Nolasco do Silva, Marcos Tadeu
    dos Santos Vilela, Maria Marluce
    SAO PAULO MEDICAL JOURNAL, 2007, 125 (04): : 205 - 209
  • [9] Metabolic complications of antiretroviral therapy in HIV-infected children
    Eley, Brian
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (01) : 37 - 49
  • [10] Viral load in HIV-infected children on high activity antiretroviral therapy
    Resino, Salvador
    Bellon, Jose M.
    Antonio Leon, Juan
    Resino, Rosa
    Munoz-Fernandez, M. Angeles
    MEDICINA CLINICA, 2007, 128 (02): : 49 - 51